CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas (FCF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Bachelor's degree in Biological Sciences - Molecular Biology Modality from the State University of Campinas (UNICAMP - 2000), a doctorate and post-doctorate in Sciences (Biology - Genetics) from the University of São Paulo (USP - 2006). She is currently an Associate Professor III at FCF/USP and coordinates the graduate Program in Biochemical-Pharmaceutical Technology (08/2024 CAPES 5.0 in the Pharmacy Area). She has experience in the area of #8203;#8203;Molecular Biology with an emphasis on the Study of Molecular and Biological Functions of Genes involved in cellular processes such as: cancer and resistance to antitumor drugs. She conducts research on heterologous protein production in microorganisms such as bacteria and yeast and protein engineering for the production of biopharmaceuticals, such as the enzyme asparaginase, used in the treatment of Childhood Acute Lymphoid Leukemia. She was coordinator of the USP team in the iGEM global synthetic biology competition from 2018-2023; in 2021 the team was classified as Top10 best in the world in the competition. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
L-asparagine (Asn) restriction has been an efficient strategy for the therapy of several cancers, especially hematological ones. Clinically, the best-known example of performing this restriction is the application of the enzyme L-asparaginase, responsible for hydrolyzing Asn into aspartic acid (Asp) and ammonia and, secondarily, glutamine (Gln) into glutamic acid (Glu) and ammonia. Recent…
Acute Lymphoblastic Leukemia (ALL) is the cancer with the highest incidence in the age group of 3 to 5 years. Therapy for the treatment of ALL utilizes, among other drugs, the bacterial L-asparaginase enzyme of Escherichia coli (Ec_ASNase) and as a second option that of D. chrysanthemi (Er_ASNase). Immunogenic reactions are the major side effects related to ASNase use, and the formation o…
L-asparaginase (L-ASNase) is a biopharmaceutical widely used in treating leukemia, especially in Brazil. However, the available commercial formulations are comprised of proteins from bacterial origin, present high molecular weight and they are active only when tetrameric. Thus, problems such as uniformity in drug formulation, allergic reactions and silent inactivation of the enzyme by ant…
(Only some records are available in English at this moment)
Several antineoplastic treatments currently used only explore the compatibility and affinity between the physicochemical nature of the drug and its receptor. However, this type of interaction based on parameters such as presence/absence is responsible for the side effects observed in patients undergoing chemotherapy, as for different types of cancer, it is noted that tumor cells are disti…
Human strongyloidiasis, caused by the nematode Strongyloides stercoralis, is a neglected tropical disease with more than 600 million people infected worldwide. Traditional diagnosis of strongyloidiasis, based on the detection of parasite larvae in feces, is inefficient due to its low sensitivity requiring several fecal samples to confirm the clinical suspicion. On the other hand, detectio…
Melanoma is an aggressive skin neoplasm with high plasticity, drug resistance and a propensity to metastasize. 50% of patients with this disease have a mutation in the BRAF protein kinase, which results in exacerbated activation of the MAPK pathway. Patients with this mutation are eligible to be treated with MAPK inhibitors, but may exhibit drug resistance and increased tumor invasiveness…
Melanoma is a malignant skin neoplasm with high plasticity, chemoresistance, and propensity to metastasis. A significant percentage of patients with this disease have BRAFV600E mutation and can be treated with Vemurafenib. Although this drug has an effective initial response, a significant number of patients have tumor resistance and disease progression after a short period of treatment i…
L-Asparaginase (L-ASNase) is an important biopharmaceutical used for the treatment of acute lymphoblastic leukemia. Since L-ASNase is a biological product isolated from bacteria, extensive purification steps are necessary to obtain a pure preparation, which in turn, negatively impacts the costs related to its manufacturing. More economical and efficient alternatives to obtain this bioprod…
A significant number of patients with acute leukemia of lymphocytic (ALL), malignant cells have a metabolic defect in the synthesis of asparagine (Asn), depending on an exogenous source of this amino acid to survive. The enzyme L-asparaginase is used in the treatment of this disease in order to exhaust the stocks of asparagine in the bloodstream required for tumor cells. Although this enz…
(Only some records are available in English at this moment)
L-Asparaginase (ASNase) is a L-asparagine amidohydrolase used as first line of acute lymphoblastic leukemia (ALL) treatment. ASNase is able to catalyze the hydrolysis of asparagine, depleting this amino acid from the bloodstream. ALL cells depend on obtaining asparagine from the bloodstream for protein synthesis and cell proliferation, since they are not able to express, or express low le…
L-Asparaginase (L-ASNase) is a key component in the treatment of acute lymphoblastic leukemia (ALL). The introduction of this biopharmaceutical product in pediatric medical protocols improved ALL survival rates to approximately 90%. However, most L-ASNases in the market, especially the L-ASNase isolated from Erwinia chrysanthemi, display a relatively high immunogenicity and a short half-l…
| 6 / 5 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 21 / 17 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 32 / 27 | All research grants and scholarships |
| Associated processes | |